Revolution Medicines, Inc.

Good day, and thank you for standing by. Welcome to the Revolution Medicine's Quarter 1 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1 1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Ryan A.C., Senior Vice President of Corporate Affairs. Please go ahead.

Thank you, and welcome everyone to the first quarter 2025 earnings call. Joining me on today's call are Dr. Mark Goldsmith, Revolution Medicine's Chairman and Chief Executive Officer, Dr. Steve Kelsey, our President of R&D, Dr. Wei Lin, our Chief Medical Officer, and Jack Anders, our Chief Financial Officer. I'd like to inform you that certain statements we make during this call will be forward-looking. Because such statements deal with future events and are subject to many risks and uncertainties, actual results may differ materially from those in the forward-looking statements. For a full discussion of these risks and uncertainties, please review our annual report on Form 10-K and our quarterly reports on Form 10-Q that are filed with the U.S. Securities and Exchange Commission. This afternoon, we released financial results for the quarter ended March 31st, 2025, and recent corporate updates. The press release is available on the investor section of our website at revmed.com, along with an updated investor presentation, which we will be referencing during today's call. With that, I'll turn the call over to Dr. Mark Goldsmith, Revolution Medicine's Chairman and Chief Executive Officer.

Mark? Thanks, Ryan. It's good to be with you this afternoon. Today, I'll highlight some of the progress we've made this quarter against the strategic priorities we outlined earlier this year. I'll then pass the call over to Dr. Steve Kelsey, who will walk through a strategic framework for our developing plans in non-small cell lung cancer. Dr. Wei Lin will then highlight updated data from several of our ongoing non-small cell lung cancer cohorts that provide support for our plans in lung cancer. Jack Anders will then provide a summary of our first quarter financial results before I share closing remarks and open the call to Q&A. At Revolution Medicines, we remain committed to revolutionizing treatment for patients with RAS-addicted cancers through the discovery, development, and delivery of innovative targeted medicines. We continue to make important strides in pursuit of this mission as we execute, advance, and extend our understanding of our novel RAS-on inhibitors. We believe and have increasingly been able to demonstrate that our compounds have the potential to become important therapeutic options for patients living with RAS-addicted cancers. Our first three clinical stage RAS-on inhibitors with highly differentiated and promising clinical profiles include Deraxon RACID, a groundbreaking RAS-on multi-selective inhibitor, Aliron RACID, a distinguished G12C-selective covalent inhibitor, and Zoldanracib, a highly innovative G12D-selective covalent inhibitor. We continue to make substantial progress advancing these programs with a vision to maximize the clinical impact across tumor types and lines of therapy through a mix of single agent and combination strategies. Pancreatic cancer is an important priority and our strategy involves executing on the ongoing Phase III RASOLUTE-302 trial of Deraxan RACID in patients with previously treated disease while moving aggressively into earlier lines of therapy. We're working quickly to prepare for the initiation of two additional Phase III studies with Deraxan RACID in pancreatic cancer in the second half of 2025. One of these trials will be in patients with first-line metastatic disease, and is expected to compare a reference arm of patients treated with chemotherapy to two investigational arms, one with patients treated with duraxone-racib monotherapy and one with patients treated with duraxone-racib plus chemotherapy. The other early-line trial will be as adjuvant treatment for patients with resectable pancreatic cancer who have undergone surgery and perioperative therapy, typically including chemotherapy. In addition to this robust plan for Draxon RASib to play an important role in the treatment of pancreatic cancer across lines of therapy, we have similar ambitions for broad development in RAS mutant non-small cell lung cancer. The principal focus of today's call is to provide further color and support for our non-small cell lung cancer strategy, and I'd like to invite Dr. Steve Kelsey to walk you through our current conceptual framework. Steve?